Vemurafenib (Zelboraf) with longer follow-up. Metastatic melanoma: a few extra months of life, but many adverse effects.
Further analysis of the unblinded trial described in the initial clinical evaluation suggests that vemurafenib prolongs survival by a median of about 4 months compared with dacarbazine. The adverse effects of vemurafenib are frequent and sometimes serious. More data are needed on renal and pancreatic toxicity and the risk of extracutaneous cancers.